Generic Rescriptor

There are currently no generic Rescriptor products available on the market. The patent for the drug expires in October 2013, however, which means that other drug companies can begin manufacturing a generic version at that time. It is important to know that delavirdine sulfate is the active ingredient in Rescriptor, but is not the same as generic Rescriptor.

Rescriptor Drug Information

Generic Rescriptor: An Overview

Rescriptor^® (delavirdine mesylate) is a prescription medication for HIV and AIDS. It is part of a group of medications known as non-nucleoside reverse transcriptase inhibitors (NNRTIs). It is approved to be used only in combination with other HIV medications.

Rescriptor is made by Pfizer, Inc. It is currently under the protection of patents that prevent any generic Rescriptor from being manufactured in the United States.

When Will Generic Rescriptor Be Available?

The first patent for Rescriptor currently expires in October 2013. This is the earliest possible date that a generic version of the drug could become available. However, other circumstances could come up to extend the exclusivity period of the drug beyond 2013. This could include such things as other patents for specific Rescriptor uses or lawsuits. Once all the patents expire, several companies will likely begin manufacturing a generic Rescriptor drug.

Is Delavirdine the Same as Generic Rescriptor?

No -- delavirdine is the active ingredient in Rescriptor, but is not a generic version of it. What can be confusing is that, oftentimes, the active ingredient of any drug is referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.